DelveInsight’s, “Oncolytic Virus Cancer Therapy - Pipeline Insight, 2022,” report provides comprehensive insights about 40+ companies and 80+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Oncolytic Virus Cancer Therapy: Overview
Oncolytic virus (OV) cancer therapies are the virus based therapeutic strategies that infect and destroy cancer cells, and therefore act as an in situ cancer vaccine by releasing tumor-specific antigens. Viruses such as myxoma virus or reovirus have inherent selectivity to tumor cells, while being nonpathogenic to healthy human cells. On the other hand, other OVs, including adenovirus, herpes simplex virus type-1 (HSV-1), and vesicular stomatitis virus (VSV), have been genetically engineered to function as vectors to boost anti-tumor immune responses. The therapeutic efficacy of Oncolytic viruses depends on two main modes of action: First, Oncolytic viruses can inhibit protein synthesis of tumor cells and destroy infected tumor cells by self-replication. After viral infection, Oncolytic viruses continue self-replication until the cell bursts; Second, Oncolytic viruses can recruit and activate tumor-infiltrating immune cells by releasing a large amount of tumor antigens and secreting cytokines. Oncolytic virus cancer therapies can be used for diagnosis as well treatment of cancer. The anti-tumor efficacies of these OVs have been evaluated in many preclinical and clinical studies as monotherapy and combination therapy.
"Oncolytic Virus Cancer Therapy - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Oncolytic virus cancer therapy pipeline landscape is provided which includes the disease overview and Oncolytic virus cancer therapy treatment guidelines. The assessment part of the report embraces, in depth Oncolytic virus cancer therapy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Oncolytic virus cancer therapy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Oncolytic Virus Cancer Therapy R&D. The therapies under development are focused on novel approaches for Oncolytic Virus Cancer Therapy.
This segment of the Oncolytic Virus Cancer Therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Oncolytic Virus Cancer Therapy Emerging Drugs
CG0070: CG Oncolgy
CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070, first replicates inside the tumor’s cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body’s own white blood cells. CG0070 is in development for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators. The therapy is in clinical development for the treatment of Bladder cancer and preclinical studies for solid tumors. In advanced clinical studies, CG0070 has been shown to be a safe and efficacious agent in NMIBC following BCG failure.
ONCOS-102: Targovax
ONCOS-102 is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal malignancies and has shown promising clinical results both as monotherapy and in combination with chemotherapy, and a checkpoint inhibitor. In February 2021, Targovax announced that ONCOS-102 has received Fast-Track designation in malignant pleural mesothelioma from the US FDA.
Further product details are provided in the report……..
This segment of the report provides insights about the different Oncolytic Virus Cancer Therapy drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 40+ key companies which are developing the Oncolytic Virus Cancer Therapy. The companies which have their Oncolytic Virus Cancer Therapy drug candidates in the most advanced stage, i.e. Phase III include, CG Oncolgy.
DelveInsight’s report covers around 80+ products under different phases of clinical development like
Oncolytic Virus Cancer Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Oncolytic Virus Cancer Therapy Market according to the key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Oncolytic Virus Cancer Therapy drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Oncolytic Virus Cancer Therapy: Overview
Pipeline Therapeutics
Therapeutic Assessment
Oncolytic Virus Cancer Therapy – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Oncolytic Virus Cancer Therapy Collaboration Deals
Late Stage Products (Phase III)
CG0070: CG Oncolgy
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
ONCOS-102: Targovax
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Oncolytic Virus Cancer Therapy Key Companies
Oncolytic Virus Cancer Therapy Key Products
Oncolytic Virus Cancer Therapy- Unmet Needs
Oncolytic Virus Cancer Therapy- Market Drivers and Barriers
Oncolytic Virus Cancer Therapy- Future Perspectives and Conclusion
Oncolytic Virus Cancer Therapy Analyst Views
Oncolytic Virus Cancer Therapy Key Companies
Appendix
List of Table
Table 1: Total Products for Oncolytic Virus Cancer Therapy
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Oncolytic Virus Cancer Therapy
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Affinia Therapeutics
• Lacerta Therapeutics
• Lokon Pharma AB
• Merck Sharp & Dohme Corp.
• Wuhan Binhui Biotechnology
• CG oncology
• BioVex Limited
• Oncolys BioPharma Inc.
• Replimmune
• Transgene
• Sorrento therapeutics
• ORCA therapeutics
• TILT Biotherapeutics
• Bioeclipse therapeutics
• Oncolys BioPharma
• Oncorus
• DNAtrix
• OncoMyx
• Vyriad
• VCN Biosciences
• Boehringer Ingelheim
• IconOVir
• Immugene
• AbbVie
• Turnstone Biologics
